Sugi Predict

Sugi Predict / Compounds / SCHEMBL520787

SCHEMBL520787

SCHEMBL520787

Nc1ccc(F)c(N2CCOCC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ GAA P10253 2/20 0.62
▸ ALDH1A1 P00352 5/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ GFER P55789 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ LGMN Q99538 2/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ HPGD P15428 4/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209737 0.86 MAPT (0.67) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL29822510 0.86 MAPT (0.67) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL14280213 0.81 LGMN (0.71) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL19212214 0.81 ALDH1A1 (0.47) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL25183852 0.81 ALDH1A1 (0.59) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL4381301 0.80 MAPT (0.59) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL6645764 0.80 MAPT (0.44) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL27631552 0.80 PRKDC (0.51) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL9300032 0.79 MAPT (0.60) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL24507284 0.79 MAPT (0.77) MAPTSMN1; SMN2GAAALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117917400-A 2-Methyl-4-quinolinone compound, and pharmaceutical composition and application thereof 暨南大学 2024-04-23 — — CN disclosed
EP-4259145-A1 ALK-5 INHIBITORS AND USES THEREOF Sumitomo Pharma Oncology, Inc. (US) 2023-10-18 — — EP disclosed
US-11746103-B2 ALK-5 inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-09-05 — — US disclosed
US-11746103-B2 ALK-5 inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-09-05 — — US disclosed
US-11746103-B2 ALK-5 inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-09-05 — — US disclosed
CN-116546986-A ALK-5 inhibitors and uses thereof 住友制药肿瘤公司 2023-08-04 — — CN disclosed
US-20220315563-A1 ALK-5 INHIBITORS AND USES THEREOF SUMITOMO PHARMA ONCOLOGY, INC. 2022-10-06 — — US disclosed
US-20220315563-A1 ALK-5 INHIBITORS AND USES THEREOF SUMITOMO PHARMA ONCOLOGY, INC. 2022-10-06 — — US disclosed
WO-2022126133-A1 ALK-5 INHIBITORS AND USES THEREOF SUMITOMO PHARMA ONCOLOGY,INC. (US) 2022-06-16 — — WO disclosed
WO-2022126133-A1 ALK-5 INHIBITORS AND USES THEREOF SUMITOMO PHARMA ONCOLOGY,INC. (US) 2022-06-16 — — WO disclosed
US-20170002005-A1 Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins LIFE MOLECULAR IMAGING LIMITED (GB) 2017-01-05 — — US disclosed
WO-2015110263-A1 CARBAZOLE AND CARBOLINE COMPOUNDS FOR USE IN THE DIAGNOSIS, TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH AMYLOID OR AMYOLID-LIKE PROTEINS AC IMMUNE SA (CH) 2015-07-30 — — WO disclosed
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 — — EP disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 — — US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 — — US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 — — EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315563-A1 ALK-5 INHIBITORS AND USES THEREOF ACVR1, ALK, ACVRL1 MAPT 4162/4885SMN1; SMN2 3355/4885GAA 331/4885
US-20170002005-A1 Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins APP, BACE1, PSEN1 MAPT 8/4885SMN1; SMN2 1891/4885GAA 659/4885
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 MAPT 3109/4885SMN1; SMN2 4722/4885GAA 3085/4885
US-11746103-B2 ALK-5 inhibitors and uses thereof ACVR1, ALK, ACVRL1 MAPT 4162/4885SMN1; SMN2 3355/4885GAA 331/4885
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA MAPT 1412/4885SMN1; SMN2 4406/4885GAA 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.